Rafarma Pharmaceuticals, Inc. (RAFA) Stock

About Rafarma Pharmaceuticals, Inc.

Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Rafarma Pharmaceuticals, Inc. is headquartered in US.

Rafarma Pharmaceuticals, Inc. (RAFA) stock trades at $0.02 with a market capitalization of $2.11M. The stock is valued at a price-to-earnings (P/E) ratio of 10.43, price-to-book of 0.20, price-to-sales of 0.24. Over the past 52 weeks the stock has ranged between $0.00 and $0.10, and currently trades 80.0% below its 52-week high.

On profitability, Rafarma Pharmaceuticals, Inc. generates a return on equity (ROE) of 2.00%, return on capital employed of 3.18%, an operating margin of 3.85%, a net profit margin of 2.42%.

Official website: www.rafarma.com